Their Tier 2 hasn't made its impact yet and the rate of increase on prescriptions has dropped based on weekly data. IMO, this will need a couple of full quarters of sales data AND a firm "Yes" or "NO" on NCE to remove uncertainty before they'll do anything but straddle the sixes and sevens.
i sold it the day it was approved,because my friend who is a chemist for phizer said there was no way in hell it would ever get nce.she said the basic ingredient was the same as in lovaza.yes it is a better drug-but that means nothing in this case.the president of amarin fishy joe just said sales are slowing down,not a good sign ,dump it now and cut your losses.
I agree. I don't think AMRN is all it's cracked up to be, and without NCE, it goes lower. I would sell it or put a stop in in you're trying to trade it. Small losses are ok- big ones are not. Good luck....
looks like hedge funds and shorts are eating it up with many other biotechs right now...but long term will tell..hurts short term'' good thing for sarepta and ''gild'' and a few others to off set short term loss of value.